Serena Silver joined Accent in September 2022 as Vice President of Biology, bringing more than 15 years of experience in target and drug discovery. Prior to joining Accent, Serena was Vice President of Discovery Biology and Technologies at Fulcrum Therapeutics, where she led scientific teams to develop and deploy new assay modalities and complex cellular models of disease to identify targets and discover therapeutics for rare disease. Serena started her career at the Broad Institute, building a screening group in the RNAi Platform that collaborated with faculty across the Broad community to utilize functional genomics to understand disease and developmental biology and to identify potential therapeutic targets. Following her time at the Broad, she led the Target ID & Validation team at Sanofi Oncology and then led the Molecular Pharmacology group at Novartis Oncology. Serena received BAs in both Biology and English and American Literature from New York University, obtained her PhD in Biology from the Massachusetts Institute of Technology and completed a postdoctoral fellowship at Harvard Medical School.